Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Zai Lab Ltd ( (HK:9688) ) is now available.
Zai Lab has granted a new round of share options, restricted share units, and performance share units to employees under its 2024 Equity Incentive Plan, covering 45 option grantees and 471 RSU grantees. The options, totaling 268,500 ADSs with a 10-year term and four-year vesting schedule, are priced at US$20.34 per ADS, while 603,851 RSUs are granted at no purchase price.
The compensation committee said the awards, which do not carry performance targets or clawback terms, are designed to retain and motivate staff and are consistent with market practice and the company’s established approach to equity incentives. The grants expand employee ownership and are intended to align staff interests with long-term shareholder value, potentially strengthening Zai Lab’s ability to compete for talent in the biopharmaceutical sector.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$15.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands and listed in Hong Kong and on Nasdaq. The company focuses on discovering, developing, and commercializing innovative medicines, with a workforce that is incentivized through equity-based compensation aligned with global biotech industry practices.
Average Trading Volume: 9,861,692
Technical Sentiment Signal: Sell
Current Market Cap: HK$17.15B
For detailed information about 9688 stock, go to TipRanks’ Stock Analysis page.